Literature DB >> 30046740

The impact of repeated freeze-thaw cycles on antiphospholipid antibody titer.

Karel Maelegheer1, Katrien M J Devreese1.   

Abstract

BACKGROUND: Pre-analytical factors, like freeze-thaw cycles (FTC), can potentially affect results and clinical interpretation. According to the SSC-ISTH recommendations for antiphospholipid antibodies (aPL) testing, additional FTC should be avoided to maintain the best performance. Patient samples are often analyzed in batch and having one frozen sample aliquot for all aPL tests, that may hamper daily routine work-out. To use them for study or method validation purpose, sample storage in bio banks is often done in one aliquot also triggering the need for several FTC to be able to use them in different scientific projects. Taking into account the limited scientific literature, the strict guidelines and the potential benefits of repeated FTC we evaluated this pre-analytical factor.
OBJECTIVES: Evaluating the effect of repeated FTC on anticardiolipin (aCL) IgM/IgG and anti-beta-2 glycoprotein 1 (aβ2GPI) IgM/IgG antibody titer. PATIENT/
METHODS: 42 patient plasmas that were not thawed before, were retrieved from the routine archive (-80°C). All aliquots were analyzed on five consecutive days with an additional, standardized FTC every day. Mann-Withney tests for statistical differences and a concordance correlation coefficient (CCC) were calculated between the first and following FTC. RESULTS AND
CONCLUSION: For all four aPL no statistical difference or degradation from positive to negative was seen, even after five FTC. The CCC between the first and fifth FTC were between 0.98 and 1 for all four aPL. aCL IgM/IgG and aβ2GPI IgM/IgG antibody titer, over a broad titer range, are stable over time and after repeated FTC.

Entities:  

Keywords:  antibodies; anticardiolipin; antiphospholipid antibodies; beta 2‐Glycoprotein I; diagnostic tests; protein stability; routine

Year:  2018        PMID: 30046740      PMCID: PMC6055575          DOI: 10.1002/rth2.12071

Source DB:  PubMed          Journal:  Res Pract Thromb Haemost        ISSN: 2475-0379


INTRODUCTION

Beside clinical symptoms, the diagnosis of antiphospholipid syndrome (APS) is based on the presence of persistent antiphospholipid antibodies (aPL). The three main cornerstone antibodies are anticardiolipin (aCL) IgM/IgG, anti‐beta‐2 glycoprotein 1 antibodies (aβ2GPI) IgM/IgG, and lupus anticoagulant (LAC). Among many challenges in aPL measurement, the pre‐analytical conditions may influence test results.1, 2 Following the Standardization subcommittee (SSC) of the international society of thrombosis and haemostasis (ISTH) recommendations, FTC should be avoided for all aPL.3, 4 In contrast to the effect of freeze‐thawing in phospholipid‐dependent clotting assays used for LAC, there is little scientific literature for solid phase assays (SPA).5 However, APL testing is mainly performed in batch due to the potential negative influence of pre‐analytical variables, such as repeated FTC, on test results. Evaluating the effect of repeated FTC on aCL IgM/IgG and aβ2GPI IgM/IgG could generate practical benefits for routine testing. Another useful application could be the use of stored samples for research and method evaluations.

METHODS

Patient plasmas (n = 42) were selected based on routine results to cover a wide titer range for all four APL, and on availability of an unthawed aliquot (Table 1).
Table 1

Routine results for all selected patient samples (n = 42) stored in the routine archive

NegativeAround Cut offPositiveStrong positive
Range (U/ml)# samplesRange (U/mL)# samplesRange (U/ml)# samplesRange (U/mL)# samples
aCL IgG3‐12821‐34653‐543103‐48010
aCL IgM2‐18722‐27452‐707104‐23306
aβ2GPI IgM3‐9721‐48854‐883107‐27056
aβ2GPI IgG11‐18923‐9712119‐1864213‐315312

aCL, anticardiolipin; aβ2GPI, anti‐beta 2 glycoprotein I.

Routine results for all selected patient samples (n = 42) stored in the routine archive aCL, anticardiolipin; aβ2GPI, anti‐beta 2 glycoprotein I. Citrated plasma was frozen after double centrifugation.3 Samples were collected between 2012 and 2017. First analysis of each included sample was performed on aliquot not thawed before. Further, samples were analyzed on five consecutive days with an additional, standardized FTC every day (Figure 1). All analysis were performed by an automated chemiluminescent assay (HemosIL AcuStar, Instrumentation Laboratory‐Werfen, Bedford, MA, USA) using the same reagent lot for each parameter during the study.
Figure 1

Timelaps studydesign *Thawing (37°C water bath 5 minutes); **Start analysis (every day in same order); ***Freezing of all samples at −20°C

Timelaps studydesign *Thawing (37°C water bath 5 minutes); **Start analysis (every day in same order); ***Freezing of all samples at −20°C Statistical analysis was done in Medcalc (MedCalc Statistical Software version 16.4.3 (MedCalc Software bvba, Ostend, Belgium). A Mann‐Withney test for statistical differences (P < .05) between the first and following FTC was performed. If no statistical difference was obtained after five FTCs, a concordance correlation coefficient (CCC) was calculated.

RESULTS AND DISCUSSION

To exclude long term storage as a potential source of degradation, all aPL titers after one FTC were compared with the original results (initially also obtained after one FTC). No significant differences between these results were observed. An interesting feature of these results, knowing that some of these samples were already stored for 5 years, is the stability over time. Having a closer look at samples stored frozen for more than 2 years, no significant difference was seen between the initial results and the results after one FTC in the current study. The sample results, 8 for aCL IgG, aCL IgM aβ2GPI IgM, and 13 for aβ2GPI IgG, showed an excellent correlation coefficient (0.94‐0.99) between the initial results and the result after one FTC obtained in this study. Due to the limited number of samples stored more than three years, no useful statistical analysis could be performed to confirm an even longer stability. After five FTC, none of the samples degraded from positive to negative and no false positive results were seen. Also, no significant titer changes (defined as > 10%) were seen after five FTC. Between the first and following repeated FTCs a Mann‐Withney test was performed for all aPL to look for statistical significant differences in titer (Table 2). Even after five FTC none of the aPL tested gave a significant difference in results. A correlation between the titers was calculated and illustrated in Figure 2, showing graphically and mathematical, the good correlation for all four aPL with a CCC between 0.98 and 1.
Table 2

Overview of Mann‐Withney test results between the first and following freeze thaw cycle

SamplesFTC1 med(IQR)FTC2 med (IQR) P‐value (FTC1‐2)FTC3 med (IQR) P‐value (FTC1‐3)FTC4 med (IQR) P‐value (FTC1‐4)FTC5 med (IQR) P‐value (FTC1‐5)
aCL IgG2630(8‐93)32 (13‐263).869233(13‐274).741835(147‐237).734934(13‐276).7143
aCL IgM2455(13‐87)57(11‐88).852858(11‐90).76559(11‐86).725957(8‐76).8481
aβ2GPI IgM2531(8‐93)28(9‐98).823431(8‐99).690829(9‐102).778431(8‐81).7949
aβ2GPI IgG3774(22‐676)73(18‐724).935479(15‐694).864274(11‐748).905874(13‐723).9551

aCL, anticardiolipin; aβ2GPI, anti‐beta 2 glycoprotein I.

Figure 2

The CCC calculated between first and fifth FTC are graphically shown. Values above 200 U/mL are disregarded in the graph (for visual purposes), but were included in the concordance correlation coefficient calculation and showed no significant difference with values below 200 IU/ml aCL, anticardiolipin; aβ2GPI, anti‐beta‐2 glycoprotein 1; CCC, concordance correlation coefficient; FTC, freeze‐thaw cycle

Overview of Mann‐Withney test results between the first and following freeze thaw cycle aCL, anticardiolipin; aβ2GPI, anti‐beta 2 glycoprotein I. The CCC calculated between first and fifth FTC are graphically shown. Values above 200 U/mL are disregarded in the graph (for visual purposes), but were included in the concordance correlation coefficient calculation and showed no significant difference with values below 200 IU/ml aCL, anticardiolipin; aβ2GPI, anti‐beta‐2 glycoprotein 1; CCC, concordance correlation coefficient; FTC, freeze‐thaw cycle Considering the high CCC, we could exclude a significant inter‐run variability as potential influencing factor on variability of titers. For each sample, a coefficient of variation (CV) was calculated using the test result after each FTC. Comparing the median CV value (for each aPL divided in four categories as described in Table 1) with results obtained from quality control (QC) material no significant difference was found. All median sample CV values varied between 4 and 15.6% comparing to the QC CV values of these runs, between 2.3‐13.9%. These results confirm the stable character of the antibodies and the limited effect of FTC. Furthermore, 4 months later, a selection of these samples with sufficient sample volume, were additionally thawed and analyzed using another batch of reagent. No significant differences were observed between first FTC and these results. As a final test, these samples were also analyzed on a second analyzer of the same type, also resulting in non‐significant differences. Correlating results after the first FTC on analyzer 1 and results after the sixth FTC on a second analyzer a concordance correlation coefficient was found, depending on the antibody, between 0.91‐0.98. Comparing both analyzers, with a sample size varying between 13 and 23 samples, an excellent correlation coefficient of 0.99 for each antibody was found, confirming the robustness of this automated systems.6 aPL are very heterogeneous group of antibodies. The small sample size, although covering a broad titer range, may be seen as a limitation of this study. Also, all tests were performed using one and the same analytical platform. Other test systems are known to be less robust suffering from lab to lab variation or high between‐run variation.6, 7 Using this automated system excludes these variables, making it possible to exclusively evaluate the effect of freeze‐thaw cycles.

CONCLUSION

We evaluated the stability of aPL titers after several FTC. aCL and aβ2GPI IgG and IgM, over a broad titer range including samples around the cut‐off value, are stable over time and after repeated FTC. With this study, we excluded this pre‐analytical factor as source for variability in aPL titer measured by chemiluminescent assays.

AUTHOR CONTRIBUTIONS

KMJ Devreese conceived the study idea and supervised, consulted, and corrected the study design, statistical analysis and manuscript. KR Maelegheer developed the study design, performed practical and statistical analysis, and wrote the manuscript.

RELATIONSHIP DISCLOSURE

No conflicts of interest to declare.
  7 in total

Review 1.  Laboratory diagnosis of the antiphospholipid syndrome: a plethora of obstacles to overcome.

Authors:  Katrien Devreese; Marc F Hoylaerts
Journal:  Eur J Haematol       Date:  2009-02-17       Impact factor: 2.997

Review 2.  Internal quality control and external quality assurance in testing for antiphospholipid antibodies: Part I--Anticardiolipin and anti-β2-glycoprotein I antibodies.

Authors:  Emmanuel J Favaloro; Loretta Wheatland; Sue Jovanovich; Peter Roberts-Thomson; Richard C W Wong
Journal:  Semin Thromb Hemost       Date:  2012-05-08       Impact factor: 4.180

3.  Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis.

Authors:  V Pengo; A Tripodi; G Reber; J H Rand; T L Ortel; M Galli; P G De Groot
Journal:  J Thromb Haemost       Date:  2009-07-17       Impact factor: 5.824

4.  Testing for antiphospholipid antibodies with solid phase assays: guidance from the SSC of the ISTH.

Authors:  K M J Devreese; S S Pierangeli; B de Laat; A Tripodi; T Atsumi; T L Ortel
Journal:  J Thromb Haemost       Date:  2014-05       Impact factor: 5.824

Review 5.  Antiphospholipid antibody testing and standardization.

Authors:  K M J Devreese
Journal:  Int J Lab Hematol       Date:  2014-06       Impact factor: 2.877

6.  Effects of repeated freeze-thaw cycles on anticardiolipin antibody immunoreactivity.

Authors:  R L Brey; S A Cote; D L McGlasson; D A Triplett; L K Barna
Journal:  Am J Clin Pathol       Date:  1994-11       Impact factor: 2.493

7.  A multicenter study to assess the reproducibility of antiphospholipid antibody results produced by an automated system.

Authors:  K M Devreese; A Poncet; E Lindhoff-Last; J Musial; P de Moerloose; P Fontana
Journal:  J Thromb Haemost       Date:  2016-12-18       Impact factor: 5.824

  7 in total
  1 in total

1.  Stability of serum precipitins to Aspergillus fumigatus for the diagnosis of allergic bronchopulmonary aspergillosis.

Authors:  Kevin S K Lau; Chantane Yeung; Chris Carlsten
Journal:  Allergy Asthma Clin Immunol       Date:  2020-09-03       Impact factor: 3.406

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.